Aldeyra Therapeutics (Nasdaq:ALDX) - Aandelenkoers, Nieuws & Analyse

ALDX Overzicht aandelen

Aldeyra Therapeutics, Inc, een biotechnologiebedrijf, ontwikkelt en verkoopt medicijnen voor immuungemedieerde ziekten.

ALDX fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Verhandeld tegen 79.3% onder onze schatting van de reële waarde

De winst zal naar verwachting met 62.33% per jaar groeien

De winst is de afgelopen 5 jaar met 2.9% per jaar gegroeid

Analisten zijn het erover eens dat de aandelenkoers met 85.2% zal stijgen

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aanzienlijke insider-verkoop in de afgelopen 3 maanden

Volatiele aandelenkoers in de afgelopen 3 maanden

Aldeyra Therapeutics, Inc. Concurrenten

Jasper Therapeutics

NasdaqCM:JSPR

US$338.4m

iTeos Therapeutics

NasdaqGM:ITOS

US$336.7m

COMPASS Pathways

NasdaqGS:CMPS

US$309.3m

Rezolute

NasdaqCM:RZLT

US$304.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Aldeyra Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$5.40
52 Week Hoogtepunt	US$6.55
52 Week Laag	US$2.20
Bèta	1.43
11 maand verandering	2.27%
3 maanden verandering	28.88%
1 Jaar Verandering	106.90%
33 jaar verandering	-40.59%
5 jaar verandering	-11.18%
Verandering sinds IPO	-25.00%

Recent nieuws en updates

Recent updates

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment

Sep 14

Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization

Aug 04

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aug 03

Aldeyra says trial for dry eye disease candidate reached key goals

Jul 12

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Apr 19

Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts

Feb 17

Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap

Dec 23

Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?

Dec 22

Rendement voor aandeelhouders

	ALDX	US Biotechs	US Markt
7D	1.1%	1.6%	2.3%
1Y	106.9%	23.6%	35.1%

Rendement versus industrie: ALDX overtrof de US Biotechs industrie, die het afgelopen jaar een rendement 23.6 % opleverde.

Rendement versus markt: ALDX overtrof de US markt, die het afgelopen jaar een rendement opleverde van 35.1 %.

Prijsvolatiliteit

Is ALDX's price volatile compared to industry and market?
ALDX volatility
ALDX Average Weekly Movement	12.7%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: De aandelenkoers van ALDX is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 13% ) van ALDX is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2004	10	Todd Brady	www.aldeyra.com

Aldeyra Therapeutics, Inc, een biotechnologiebedrijf, ontwikkelt en commercialiseert geneesmiddelen voor immuungemedieerde ziekten. De belangrijkste productkandidaat is reproxalap, een reactieve aldehyde species (RASP)-modulator, die zich in Fase III van het klinisch onderzoek bevindt voor de behandeling van droge-ogenaandoeningen. Het bedrijf ontwikkelt ook ADX-629, een oraal toegediende RASP-modulator voor de behandeling van COVID-19, atopische astma, psoriasis en alcoholintoxicatie; en ADX-2191, een dihydrofolaatreductaseremmer voor de behandeling van retinitis pigmentosa en zeldzame netvliesaandoeningen die worden gekenmerkt door ontsteking en gezichtsverlies.

Aldeyra Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Aldeyra Therapeutics zich tot de beurswaarde?
ALDX fundamentele statistieken
Marktkapitalisatie	US$313.15m
Inkomsten(TTM)	-US$37.87m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-8.5x

Koers/Winstverhouding

Is ALDX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ALDX resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$37.87m
Inkomsten	-US$37.87m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.64
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	15.5%

Hoe presteerde ALDX op de lange termijn?

Bekijk historische prestaties en vergelijking

ALDX Overzicht aandelen

Beloningen

Risicoanalyse

Aldeyra Therapeutics, Inc. Concurrenten

NasdaqCM:JSPR

US$338.4m

NasdaqGM:ITOS

US$336.7m

NasdaqGS:CMPS

US$309.3m

NasdaqCM:RZLT

US$304.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Chief Development Officer recently sold US$76k worth of stock

Chief Development Officer notifies of intention to sell stock

Price target increased by 8.1% to US$10.00

New minor risk - Share price stability

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Recent updates

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Chief Development Officer recently sold US$76k worth of stock

Chief Development Officer notifies of intention to sell stock

Price target increased by 8.1% to US$10.00

New minor risk - Share price stability

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Consensus EPS estimates fall by 209%

New minor risk - Profitability

No longer forecast to breakeven

Aldeyra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Consensus EPS estimates upgraded to US$0.18 loss

Forecast to breakeven in 2026

Consensus EPS estimates fall by 163%

Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

No longer forecast to breakeven

New minor risk - Profitability

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Profitability

No longer forecast to breakeven

Forecast to breakeven in 2024

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

CEO, President & Director recently sold US$581k worth of stock

CEO, President & Director notifies of intention to sell stock

Forecast to breakeven in 2024

New minor risk - Profitability

Forecast to breakeven in 2024

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 55%

Consensus revenue estimates increase by 57%

Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

Consensus revenue estimates increase by 600%

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Consensus revenue estimates decrease by 82%, EPS upgraded

Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

New minor risk - Market cap size

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease

Consensus revenue estimates decrease by 61%, EPS upgraded

Price target decreased by 13% to US$17.86

CEO, President & Director exercised options and sold US$492k worth of stock

Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc

Consensus revenue estimates increase by 36%

Consensus revenue estimates decrease by 73%, EPS upgraded

Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, Inc

Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough

Consensus revenue estimates increase by 15%

Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target increased by 8.4% to US$21.83

Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease Trials

Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease